Development of a simple genotyping method for the HLA-A∗31:01-tagging SNP in Japanese

Pharmacogenomics

Volumn 16, Issue 15, 2015, Pages 1689-1699

  Maekawa, Keiko ^a   Nakamura, Ryosuke ^a   Kaniwa, Nahoko ^a   Mizusawa, Seiho ^b   Kitamoto, Aya ^b   Kitamoto, Takuya ^b   Ukaji, Maho ^a   Matsuzawa, Yumiko ^a   Sugiyama, Emiko ^a   Uchida, Yoshimi ^a   Kurose, Kouichi ^a,c   Ueta, Mayumi ^d   Sotozono, Chie ^d   Ikeda, Hiroko ^e   Yagami, Akiko ^f   Matsukura, Setsuko ^g   Kinoshita, Shigeru ^d   Muramatsu, Masaaki ^h   Ikezawa, Zenro ^g   Sekine, Akihiro ^b,i   Furuya, Hirokazu ^j,k   Takahashi, Yukitoshi ^e   Matsunaga, Kayoko ^f   Aihara, Michiko ^g   Saito, Yoshiro ^a   more..

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c TOKYO UNIVERSITY OF MARINE SCIENCE AND TECHNOLOGY   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^f FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g YOKOHAMA CITY UNIVERSITY   (Japan)

^h TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

ⁱ CHIBA UNIVERSITY   (Japan)

^j KOCHI UNIVERSITY   (Japan)

^k KUGA Building   (Japan)

more..

Author keywords

carbamazepine; PCR RFLP; screening test; Stevens Johnson syndrome toxic epidermal necrolysis

Indexed keywords

CARBAMAZEPINE; GENOMIC DNA; HLA A ANTIGEN; ANTICONVULSIVE AGENT; DNA; GENETIC MARKER; HLA-A31 ANTIGEN;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC RISK; GENOTYPING TECHNIQUE; HAPLOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; JAPANESE (PEOPLE); MALE; MIDDLE AGED; PATIENT IDENTIFICATION; POLYMERASE CHAIN REACTION; PPP1R11 GENE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; ZNRD1AS1 GENE; ASIAN CONTINENTAL ANCESTRY GROUP; GENETIC MARKER; GENETICS; GENOTYPE; JAPAN; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

ANTICONVULSANTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARBAMAZEPINE; DNA; GENE FREQUENCY; GENETIC MARKERS; GENOTYPE; HLA-A ANTIGENS; HUMANS; JAPAN; LINKAGE DISEQUILIBRIUM; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; STEVENS-JOHNSON SYNDROME; TREATMENT OUTCOME;

EID: 84949227945     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.15.115     Document Type: Article

References (31)

1. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 209(2), 123-129 (2005).
2. Kaniwa N, Saito Y. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. J. Hum. Genet. 58(6), 317-326 (2013).
3. McCormack M, Alfirevic A, Bourgeois S et al. HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134-1143 (2011).
4. Ozeki T, Mushiroda T, Yowang A et al. Genome-wide association study identifies HLA-A3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20(5), 1034-1041 (2011).
5. Chen P, Lin JJ, Lu CS et al. Carbamazepine-induced toxic effects and HLA-B1502 screening in Taiwan. N. Engl. J. Med. 364(12), 1126-1133 (2011).
6. Amstutz U, Shear NH, Rieder MJ et al. Recommendations for HLA-B15:02 and HLA-A31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 55(4), 496-506 (2014).
7. Middleton D. History of DNA typing for the human MHC. Rev. Immunogenet. 1(2), 135-156 (1999).
8. Aoki M, Hosono N, Takata S et al. New pharmacogenetic test for detecting an HLA-A31:01 allele using the InvaderPlus assay. Pharmacogenet. Genomics 22(6), 441-446 (2012).
9. Uchiyama K, Kubota F, Ariyoshi N et al. Development of a simple method for detection of the HLA-A31:01 allele. Drug Metab. Pharmacokinet. 28(5), 435-438 (2013).
10. Niihara H, Kohno K, Taketani T et al. Simple and rapid detection of HLA-A31:01 for prediction of carbamazepineinduced hypersensitivity using loop-mediated isothermal amplification method. J. Dermatol. Sci. 74(1), 88-92 (2014).
11. Cheung YK, Kwok M, Chan E et al. Rapid detection of HLA-A31:01 allele in DNA and blood samples using loopmediated isothermal amplification. Br. J. Dermatol. 171(1), 90-96 (2014).
12. de Bakker PI, McVean G, Sabeti PC et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat. Genet. 38(10), 1166-1172 (2006).
13. Mallal S, Phillips E, Carosi G et al. HLA-B5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
14. Colombo S, Rauch A, Rotger M et al. The HCP5 singlenucleotide polymorphism: a simple screening tool for prediction of hypersensitivity reaction to abacavir. J. Infect. Dis. 198(6), 864-867 (2008).
15. Rodriguez-Novoa S, Cuenca L, Morello, J et al. Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B5701. J. Antimicrob. Chemother. 65(8), 1567-1569 (2010).
16. Sanchez-Giron F, Villegas-Torres B, Jaramillo-Villafuerte K et al. Association of the genetic marker for abacavir hypersensitivity HLA-B5701 with HCP5 rs2395029 in Mexican Mestizos. Pharmacogenomics 12(6), 809-814 (2011).
17. Galvan CA, Elbarcha OC, Fernandez EJ et al. Rapid HCP5 single-nucleotide polymorphism genotyping: a simple allelespecific PCR method for prediction of hypersensitivity reaction to Abacavir. Clin. Chim. Acta 412(15-16), 1382-1384 (2011).
18. Maekawa K, Nishikawa J, Kaniwa N et al. Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B58:01: a partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrome/toxic epidermal necrolysis in Japanese. Drug Metab. Pharmacokinet. 27(4), 447-450 (2012).
19. Kitajima H, Sonoda M, Yamamoto K. HLA and SNP haplotype mapping in the Japanese population. Genes Immun. 13(7), 543-548 (2012).
20. Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch. Dermatol. 129(1), 92-96 (1993).
21. Hashimoto K, Iijima M, Shiohara T et al. Toxic epidermal necrolysis. In: Handling Manual for Individual Severe Adverse Reactions (Volume 1). Japan Pharmaceutical Information Center, Tokyo, Japan, 21-35 (2007).
22. Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J. Invest. Dermatol. 128(1), 35-44 (2008).
23. Kaniwa N, Saito Y, Aihara M et al. HLA-B1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51(12), 2461-2465 (2011).
24. Kaniwa N, Sugiyama E, Saito Y et al. Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics 14(15), 1821-1831 (2013).
25. International HapMap Project. http://hapmap.ncbi.nlm.nih.gov/index.html.en
26. Kashiwagi M, Aihara M, Takahashi Y et al. Human leukocyte antigen genotypes in carbamazepine-induced severe cutaneous adverse drug response in Japanese patients. J. Dermatol. 35(10), 683-685 (2008).
27. Kim SH, Lee KW, Song WJ et al. Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans. Epilepsy Res. 97(1-2), 190-197 (2011).
28. Genin E, Chen DP, Hung SI et al. HLA-A31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. Pharmacogenomics J. 14(3), 281-288 (2013).
29. Hsiao YH, Hui RC, Wu T et al. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations. J. Dermatol. Sci. 73(2), 101-109 (2013).
30. Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 312(5), 525-534 (2014).
31. Erlich RL, Jia X, Anderson S et al. Next-generation sequencing for HLA typing of class I loci. BMC Genomics 12, 42 (2011).